Mentioned in ?
References in periodicals archive ?
(Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today provided general corporate and pipeline updates and reported financial results for the second quarter of 2019.
The researchers focused on the relationship between PKA and adenylyl cyclase (AC), an enzyme involved in cyclic AMP (cAMP) production, a cellular messenger with a critical role in vascular cell function.
- The approved drugs in the IBS space target chloride channel 2, calcium channel, serotonin 5-HT3 receptor, guanylyl cyclase c receptor, opioid receptors, gram-negative bacteria, and RNA polymerase.
Cyclerion Therapeutics announced its launch as an independent, publicly traded clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase, or sGC, pharmacology to discover, develop and commercialize treatments for serious and orphan diseases.
The agreement is related to an investigational compound targeting the pituitary adenylate cyclase receptor 1 (PAC1) in non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and various other gastrointestinal and liver diseases.
Its role is reflected in the dopamine binding and inhibiting the activity of adenylyl cyclase, an enzyme from the lyase group which is a part of the cyclic adenosine monophosphate (cAMP) signal pathway which, in addition to the phosphatidylinositol pathway, represents the way in which the G-protein coupled receptors transmit a signal.
The product is an orally administered central nervous system (CNS) penetrant soluble guanylate cyclase (sGC) stimulator that is being developed for the treatment of serious and orphan CNS disorders.
focused on combining Ironwood's expertise in soluble guanylate cyclase (sGC) and our proprietary NO-donating research platform to generate new molecules with therapeutic potential; as well as progressed in our collaboration with Re-Vana.
This new study used genome sequencing and found mutations in one specific gene related to obesity: adenylate cyclase 3 (ADCY3).
IW-1973 is an investigational soluble guanylate cyclase (sGC) stimulator which plays an important role in regulating diverse physiological processes such as blood flow, inflammation, fibrosis, and metabolism.
One such therapy for refractory vasodilatory shock is methylene blue which is a guanylyl cyclase inhibitor and inhibits production of cGMP and therefore inhibits dephosphorylation of myosin, decreasing vasodilation [1].